Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GH Stock Forecast 2026-2027
$85.49
Current Price
$11.21B
Market Cap
Buy 22
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to GH Price Targets
+110.6%
To High Target of $180.00
+52.1%
To Median Target of $130.00
+5.3%
To Low Target of $90.00
GH Price Momentum
-6.3%
1 Week Change
-18.5%
1 Month Change
+99.3%
1 Year Change
-16.3%
Year-to-Date Change
-29.2%
From 52W High of $120.74
+135.1%
From 52W Low of $36.36
📊 TOP ANALYST CALLS
Did GH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Guardant Health is one of their latest high-conviction picks.
Latest GH Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, GH has a bullish consensus with a median price target of $130.00 (ranging from $90.00 to $180.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $85.49, the median forecast implies a 52.1% upside. This outlook is supported by 22 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Puneet Souda at Leerink Partners, projecting a 110.6% upside. Conversely, the most conservative target is provided by Daniel Markowitz at Evercore ISI Group, suggesting a 5.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GH Analyst Ratings
22
Buy
2
Hold
0
Sell
GH Price Target Range
Low
$90.00
Average
$130.00
High
$180.00
Current: $85.49
Latest GH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Piper Sandler | David Westenberg | Overweight | Maintains | $130.00 |
| Feb 20, 2026 | Stifel | Daniel Arias | Buy | Maintains | $130.00 |
| Feb 20, 2026 | Evercore ISI Group | Daniel Markowitz | In-Line | Maintains | $110.00 |
| Feb 20, 2026 | Citigroup | Patrick Donnelly | Buy | Maintains | $150.00 |
| Feb 20, 2026 | Leerink Partners | Puneet Souda | Outperform | Maintains | $180.00 |
| Feb 20, 2026 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $125.00 |
| Feb 20, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $135.00 |
| Feb 20, 2026 | JP Morgan | Casey Woodring | Overweight | Maintains | $130.00 |
| Feb 20, 2026 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $135.00 |
| Feb 20, 2026 | BTIG | Mark Massaro | Buy | Maintains | $145.00 |
| Feb 17, 2026 | Baird | Catherine Schulte | Outperform | Initiates | $120.00 |
| Jan 26, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $135.00 |
| Jan 9, 2026 | Stifel | Daniel Arias | Buy | Maintains | $120.00 |
| Jan 5, 2026 | Evercore ISI Group | Daniel Markowitz | In-Line | Downgrade | $105.00 |
| Jan 5, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $115.00 |
| Dec 22, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $125.00 |
| Dec 17, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $120.00 |
| Dec 15, 2025 | Leerink Partners | Puneet Souda | Outperform | Maintains | $155.00 |
| Dec 15, 2025 | JP Morgan | Casey Woodring | Overweight | Maintains | $120.00 |
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $120.00 |
Guardant Health Inc. (GH) Competitors
The following stocks are similar to Guardant Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GH
Guardant Health
mkt cap
11.21B
Guardant Health Inc. (GH) Financial Data
Guardant Health Inc. has a market capitalization of $11.21B with a P/E ratio of -25.8x. The company generates $982.02M in trailing twelve-month revenue with a -42.4% profit margin.
Revenue growth is +39.4% quarter-over-quarter, while maintaining an operating margin of -42.9% and return on equity of +419.2%.
Valuation Metrics
Market Cap
$11.21B
Enterprise Value
$11.53B
P/E Ratio
-25.8x
PEG Ratio
-2.3x
Price/Sales
11.2x
Growth & Margins
Revenue Growth (YoY)
+39.4%
Gross Margin
+64.6%
Operating Margin
-42.9%
Net Margin
-42.4%
EPS Growth
+39.4%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
4.8x
Debt/Equity
-17.2x
ROE
+419.2%
ROA
-15.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Guardant Health Inc. (GH) Business Model
About Guardant Health Inc.
What They Do
Develops precision oncology blood and tissue tests.
Business Model
The company generates revenue by providing a range of blood and tissue-based tests for cancer diagnosis and treatment, billing through insurance reimbursements and contracts with healthcare providers and pharmaceutical partners. Its products, including various liquid biopsy tests and genomic profiling platforms, are designed to support oncologists in making informed treatment decisions.
Additional Information
Founded in 2011 and headquartered in Palo Alto, California, the company is advancing non-invasive cancer diagnostics and personalized medicine, leveraging vast data sets and advanced analytics. Guardant Health serves both domestic and international markets, focusing on improving cancer treatment outcomes and facilitating clinical trials.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,490
CEO
Dr. Helmy Eltoukhy Ph.D.
Country
United States
IPO Year
2018
Website
guardanthealth.comGuardant Health Inc. (GH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
Mar 05, 2026
By Debanjana Dey
Microcap Article
Latest News
Guardant Health, Inc. (GH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
3 days ago
Quick Summary
Guardant Health, Inc. (GH) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments and insights relevant to investors.
Why It Matters
Guardant Health's presentation at a major healthcare conference can influence investor sentiment, potentially affecting stock price and market perception of the company's growth prospects and innovations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The firm initiated a position in Tractor Supply due to recent share weakness, while selling Tyler Technologies due to decelerating revenue growth.
Why It Matters
The excerpt highlights a strategic investment shift, with a new position in Tractor Supply due to attractive pricing, while exiting Tyler Technologies due to declining growth, indicating a focus on quality and performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Guardant Health's Shield™ blood test for colorectal cancer screening is now widely available through Quest Diagnostics, enhancing access to innovative diagnostics for clinicians nationwide.
Why It Matters
Guardant Health's Shield test accessibility via Quest Diagnostics enhances its market reach, potentially increasing revenue and solidifying its position in precision oncology, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
bioAffinity focuses on its CyPath Lung test for early lung cancer detection, while Guardant Health is expanding its liquid biopsy and screening offerings.
Why It Matters
The competition between bioAffinity's sputum test and Guardant Health's liquid biopsy could influence market share and innovation in early lung cancer detection, impacting stock performance and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Guardant Health partners with Patrick Dempsey to promote colorectal cancer screening and the FDA-approved Shield® blood test, enhancing awareness among eligible individuals aged 45 and older.
Why It Matters
Guardant Health's partnership with Patrick Dempsey enhances brand visibility and credibility, potentially boosting demand for its Shield® blood test and positively impacting revenue growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Guardant Health, Inc. has launched "Shield Across America," a mobile screening tour promoting its FDA-approved blood test for colorectal cancer across over 100 U.S. communities.
Why It Matters
Guardant Health's nationwide mobile screening tour for its FDA-approved blood test could drive significant revenue growth and increase market penetration, positively impacting its stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About GH Stock
What is Guardant Health Inc.'s (GH) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Guardant Health Inc. (GH) has a median price target of $130.00. The highest price target is $180.00 and the lowest is $90.00.
Is GH stock a good investment in 2026?
According to current analyst ratings, GH has 22 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $85.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GH stock?
Wall Street analysts predict GH stock could reach $130.00 in the next 12 months. This represents a 52.1% increase from the current price of $85.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Guardant Health Inc.'s business model?
The company generates revenue by providing a range of blood and tissue-based tests for cancer diagnosis and treatment, billing through insurance reimbursements and contracts with healthcare providers and pharmaceutical partners. Its products, including various liquid biopsy tests and genomic profiling platforms, are designed to support oncologists in making informed treatment decisions.
What is the highest forecasted price for GH Guardant Health Inc.?
The highest price target for GH is $180.00 from Puneet Souda at Leerink Partners, which represents a 110.6% increase from the current price of $85.49.
What is the lowest forecasted price for GH Guardant Health Inc.?
The lowest price target for GH is $90.00 from Daniel Markowitz at Evercore ISI Group, which represents a 5.3% increase from the current price of $85.49.
What is the overall GH consensus from analysts for Guardant Health Inc.?
The overall analyst consensus for GH is bullish. Out of 30 Wall Street analysts, 22 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $130.00.
How accurate are GH stock price projections?
Stock price projections, including those for Guardant Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 12:49 PM UTC